Skip to main content
OpenTrials
Completed

NCT Number: NCT06211322

The Remote Monitoring of Gout Feasibility Study

In this feasibility trial, a digital follow-up treatment strategy with patient self-management app (Urika) and remote monitoring in specialist healthcare for patients with gout will be tested.

Completed

Looking for future studies?

Notify Me

Key information

About this study

In this feasibility study various outcome measures will be assessed to determine whether the app (Urika) is viable, practical, and useful. The study will include assessments of technical, operational, clinical, and trial aspects of feasibility.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or non-pregnant, non-nursing female >18 years of age at screening
  • Patients with a clinical diagnosis of gout
  • Patients who fulfil the American College of Rheumatology (ACR)/EULAR classification criteria
  • Serum urate level >360 μmol/L at inclusion
  • Having a smartphone/tablet

Exclusion criteria

  • Contraindication for urate lowering therapy
  • Unstable medical conditions (e.g,, uncontrollable hypertension, impaired liver function); known stage 3b or higher chronic kidney disease (estimated glomerular filtration (eGFR) rate/creatinine clearance <45 mL/min); severe infection or gastrointestinal bleed
  • Major co-morbidities (e.g., malignancies, severe cardiovascular disease, severe diabetes mellitus, severe respiratory diseases)
  • Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol difficult

Treatment and study plan

"Urika", a self-management application for patients with gout

Device

The self-management software application (Urika) will include information videos on gout and treatment, reminders of daily medication and blood tests, a built-in algorithm for medical dosage escalation, visualization and log of serum urate levels, motivational gamification, asynchronous chat function patient-health professionals, and a platform for remote monitoring by health professionals.

Primary outcomes

  1. Desirable feasibility level

    Time frame: Through study completion, an average of 3 months

    Acceptable overall feasibility of the app with ≥70% of the secondary endpoints indicating feasibility.

Secondary outcomes

  1. App performance and functionality

    Time frame: Through study completion, an average of 3 months

    Acceptable number of errors (≤5 errors per participant) in the performance and functionality experienced by the patients and project group members

  2. Patient-reported software usability

    Time frame: At 3 months

    Considered feasible if the System Usability Scale median score is ≥68 on a 0-100 scale, 100= best score

  3. Patient-reported experiences and perceived benefits with the app

    Time frame: At 3 months

    Open responses will be collected in semi-structured interview. No scales or instruments will be used

  4. Patient and health professionals' training requirements

    Time frame: Pre-baseline for health professionals and at baseline for patients

    Measured by registering amount of time spent (minutes) on training

  5. Patient-reported satisfaction with the app

    Time frame: At 3 months

    Measured by a numeric rating scale (NRS) 0-10, higher scores mean better outcome. Acceptable feasibility if >=70% of the participants report score >=5, otherwise considered not acceptable feasibility.

  6. Integration of workflow for health professionals

    Time frame: At screening and enrollment

    Measured by registering time spent on screening and enrollment

  7. Serum urate level

    Time frame: At 3 months

    Considered feasible if there is available data on serum urate levels for ≥90% of patients for calculation of mean levels and proportion with low serum urate level

  8. Patient-reported software functionality

    Time frame: Through study completion, an average of 3 months

    Total number of reported errors related to the software functionality (e.g., downloading, login, registration of medication, reminders, access to videos, medication adherence, registration of blood test results, urate level graph, blood test history, chat, request new prescription). Considered acceptable feasibility if the number of errors are ≤5 per patient in the performance and functionality experienced by the patients and project group members.

  9. Urate lowering therapy dose escalation

    Time frame: Through study completion, an average of 3 months

    Considered feasible if patient-reported data and the medication history in the app monitored in the platform for health personnel is available for ≥90% of patients.

  10. Patient-reported adherence to serum urate lowering therapy

    Time frame: At 3 months

    Patient-reported Medication Adherence Report Scale (MARS-5), score range 5-25, higher scores mean better adherence. Considered acceptable feasibility if >=90% of the patients complete the instrument.

  11. Acute gout flares

    Time frame: At 3 months

    Number of acute gout flares

  12. Side-effects of urate lowering therapy

    Time frame: At 3 months

    Number of side-effects registered in the app or by study nurse or study coordinator

  13. Adverse events

    Time frame: At 3 months

    Number of adverse events (incl. serious adverse events) registered by study medical doctor, study nurse or study coordinator

  14. Patient satisfaction with the follow-up care

    Time frame: At 3 months

    Measured by a single item with 5 response categories, ranging from very dissatisfied to very satisfied, higher scores mean higher satisfaction. Considered acceptable feasibility if >=70% of the participants report to be satisfied or very satisfied.

  15. Knowledge of gout and recommended treatment

    Time frame: At baseline and 3 months

    Measured by the Gout Knowledge Questionnaire, 0-10, higher scores mean better outcome. Considered acceptable feasibility if there is available total score data for >=90% of the patients.

  16. Pain related to gout

    Time frame: At 3 months

    Measured by a numeric rating scale (NRS) 0-10, lower scores mean better outcome. Considered acceptable feasibility if there is available data for >=90% of the participants.

  17. Health related quality of life

    Time frame: At 3 months

    Measured by the Euro Quality of Life 5 Dimensions 5 Levels, each item is scored 1-5, lower scores mean better outcome. Considered acceptable feasibility if there is available data for >=90% of the participants.

  18. Activity limitations

    Time frame: At 3 months

    Measured by Work Productivity and Activity Impairment (WPAI) item no.6, 0-10, lower scores mean better outcome. Considered acceptable feasibility if there is available data for >=90% of the participants.

  19. Number of consultations in specialist or primary healthcare

    Time frame: At 3 months

    Considered acceptable feasibility if there is available data for ≥90% of patients on patient-reported visits in specialist or primary healthcare

  20. Costs and time for traveling

    Time frame: At 3 months

    Considered acceptable feasibility if there is available data for ≥90% of patients on patient-reported time for travelling to the hospital

  21. Sick leave and time off work

    Time frame: At 3 months

    Considered acceptable feasibility if there is available data for ≥90% of participants using self-report

  22. Eligible patients per month

    Time frame: At enrollment

    Number of eligible patients per month.

  23. Recruitment rate

    Time frame: After enrollment

    Acceptable recruitment rate is ≥50% of eligible patients.

  24. Patient dropout

    Time frame: At 3 months

    Number of patients that withdraw from the study. Acceptable withdrawal rate is ≤20% of included patients.

  25. Trial logistics

    Time frame: At 3 months

    Acceptable overall trial logistics (Identification, screening, recruitment, patient training, data collections, monitoring blood test results, renewal of prescriptions) evaluated as Yes vs. No by the study group.

  26. Patients' app use: videos watched

    Time frame: Through study completion, an average of 3 months

    Count the number of videos watched per participant. Considered acceptable feasibility if ≥70% of the participants have watched at least 1 video.

  27. Patients' app use: registrations of daily medication adherence

    Time frame: Through study completion, an average of 3 months

    Count the number of registrations of daily medication adherence. Considered acceptable feasibility if ≥70% of the participants have registered at least 1 adherence.

  28. Patients' app use: registration of serum urate levels

    Time frame: Through study completion, an average of 3 months

    Count the number of registered serum urate levels. Considered acceptable feasibility if ≥90% of the patients register their serum urate level monthly.

  29. Patients' app use: chat messages

    Time frame: Through study completion, an average of 3 months

    Count the number of chat messages. Considered acceptable feasibility if ≥70% of the participants register at least 1 chat message.

  30. Patients' app use: flare registering

    Time frame: Through study completion, an average of 3 months

    Count the number of flare registering. Considered acceptable feasibility if ≥10% of the participants register 1 flare.

  31. Potential risk and challenges

    Time frame: At 3 months

    Incidence of hinders that could harm a successful clinical evaluation of the app in a large randomised, controlled trial.

Sponsors and collaborators

Lead sponsor

Diakonhjemmet Hospital

Other

Registry information

Official study title

The ReMonit Gout Feasibility Study

Acronym: ReMonit Gout

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Jan 18, 2024
Registry last updated
Dec 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.